ABCMdb

ABCB1 p.Val988Ala

Predicted by SNAP2:	A: N (57%), C: D (53%), D: D (91%), E: D (85%), F: D (75%), G: D (85%), H: D (85%), I: N (78%), K: D (91%), L: N (82%), M: N (66%), N: D (85%), P: D (91%), Q: D (85%), R: D (91%), S: D (80%), T: D (75%), W: D (91%), Y: D (85%),
Predicted by PROVEAN:	A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: N, K: D, L: N, M: N, N: D, P: D, Q: D, R: D, S: D, T: D, W: D, Y: D,

[switch to compact view]
Comments [show]

None has been submitted yet.

Publications
[hide] Biochemical, cellular, and pharmacological aspects... Annu Rev Pharmacol Toxicol. 1999;39:361-98. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
Annu Rev Pharmacol Toxicol. 1999;39:361-98., [PMID:10331089]

Abstract [show]
Considerable evidence has accumulated indicating that the multidrug transporter or P-glycoprotein plays a role in the development of simultaneous resistance to multiple cytotoxic drugs in cancer cells. In recent years, various approaches such as mutational analyses and biochemical and pharmacological characterization have yielded significant information about the relationship of structure and function of P-glycoprotein. However, there is still considerable controversy about the mechanism of action of this efflux pump and its function in normal cells. This review summarizes current research on the structure-function analysis of P-glycoprotein, its mechanism of action, and facts and speculations about its normal physiological role.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
47 Table 1 List of mutations in human, mouse, and hamster P-glycoproteins that affect substrate specificitya aa mutation Region Sourceb Reference H61R, F, K, M, W, Y TM 1 Human MDR1 149, 150 ABC20c G64R TM 1 Human MDR1 150 L65R TM 1 Human MDR1 150 aa78-97 EC 1 Human MDR1 151 Q128Hd TM 2 Mouse mdr3 152 R138H IC 1 Mouse mdr3 152 Q139H, R IC 1 Mouse mdr3 152 Q141V IC 1 Human MDR1 15319, Q145H IC 1 Mouse mdr3 152 E155G, K IC 1 Mouse mdr3 152 F159I IC 1 Mouse mdr3 152 D174G IC 1 Mouse mdr3 152 S176G, P IC 1 Mouse mdr3 152 K177I IC 1 Mouse mdr3 152 N179S IC 1 Mouse mdr3 152 N183S/G185V IC 1 Human MDR1 154 G183D IC 1 Mouse mdr3 152 G185V IC 1 Human MDR1 155-157 G187V IC 1 Human MDR1 153 A192T TM 3 Mouse mdr3 152 F204S EC 2 Mouse mdr3 152 W208G EC 2 Mouse mdr3 152 K209E EC 2 Mouse mdr3 152 L210I TM 4 Mouse mdr3 152 T211P TM 4 Mouse mdr3 152 I214T TM 4 Mouse mdr3 152 P223A TM 4 Human MDR1 158 G288V IC 2 Human MDR1 153 I299M, T319S, L322I, TM 5, EC3, Human MDR1 159 G324K, S351N IC 3 F335A TM 6 Human MDR1 19 F335 TM 6 Human MDR1 160 V338A TM 6 Human MDR1 161 G338A, A339P TM 6 Hamster PGY1 162, 163 A339P TM 6 Hamster PGY1 163 G341V TM 6 Human MDR1 161 K536R, Q N-NBD Human MDR1 164 ERGA → DKGT N-NBD Mouse mdr3 165 aa 522-525 T578C N-NBD Mouse mdr3 165 (Continued) G830V IC 4 Human MDR1 P866A TM 10 Human MDR1 158 F934A TM 11 Mouse mdr3 166 G935A TM 11 Mouse mdr3 166 I936A TM 11 Mouse mdr3 166 F938A TM 11 Mouse mdr3 166 S939A TM 11 Mouse mdr3 166 S939F TM 11 Mouse mdr3 167, 168 S941F TM 11 Mouse mdr1 167, 168 T941A TM 11 Mouse mdr3 166 Q942A TM 11 Mouse mdr3 166 A943G TM 11 Mouse mdr3 166 Y946A TM 11 Mouse mdr3 166 S948A TM 11 Mouse mdr3 166 Y949A TM 11 Mouse mdr3 166 C952A TM 11 Mouse mdr3 166 F953A TM 11 Mouse mdr3 166 F983A TM 12 Human MDR1 169 L975A, V981A, F983A TM 12 Human MDR1 169 M986A, V988A, Q990A, TM 12 Human MDR1 169 V991A V981A, F983A TM 12 Human MDR1 169 L975A, F983A TM 12 Human MDR1 169 L975A, V981A TM 12 Human MDR1 169 F978A TM 12 Human MDR1 19 a aa,amino acid; EC, extracellular loop; IC, intracellular loop; TM,transmembrane domain; NBD, nucleotide binding/utilization domain. Login to comment

[hide] A single amino acid residue contributes to distinc... Biochemistry. 1999 May 18;38(20):6630-9. Dey S, Hafkemeyer P, Pastan I, Gottesman MM
A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Biochemistry. 1999 May 18;38(20):6630-9., 1999-05-18 [PMID:10350482]

Abstract [show]
Both cis and trans isomers of the dopamine receptor antagonist flupentixol inhibit drug transport and reverse drug resistance mediated by the human multidrug transporter P-glycoprotein (Pgp) with a stereoselective potency. The rate of ATP hydrolysis by Pgp and photoaffinity labeling of Pgp with the substrate analogue [125I]iodoarylazidoprazosin ([125I]IAAP) are modulated by each isomer in an opposite manner, suggesting different mechanisms for the inhibitory effect on drug transport. In this study we demonstrate that substitution of a single phenylalanine residue at position 983 (F983) with alanine (F983A) in putative transmembrane (TM) region 12 selectively affects inhibition of Pgp-mediated drug transport by both isomers of flupentixol. In F983A the stimulatory effect of cis(Z)-flupentixol and the inhibitory effect of trans(E)-flupentixol on ATP hydrolysis and [125I]IAAP labeling were significantly altered. This indicates that F983 contributes to inhibition of drug transport by both isomers of flupentixol and plays an important role in stimulation and inhibition of ATP hydrolysis and [125I]IAAP labeling by cis(Z)- and trans(E)-flupentixol, respectively. The near-wild-type level of drug transport by the F983A Pgp mutant dissociates susceptibility to inhibition by flupentixol from drug translocation, indicating the allosteric nature of the flupentixol interaction. The inhibitory effects of cyclosporin A on drug transport, drug-stimulated ATP hydrolysis, and [125I]IAAP labeling as well as the stimulatory effect of verapamil on ATP hydrolysis by Pgp were minimally affected by substitution of F983, suggesting no global alteration in the structural and functional integrity of the mutant. Taken together, our data suggest that distinct mechanisms of inhibition of Pgp-mediated drug transport by the cis and trans isomers of flupentixol are mediated through a common site of interaction.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
127 In a recent study, seven amino acid residues, L975, V981, F983, M986, V988, Q990, and V991, in the putative TM 12 of human Pgp were substituted individually by alanine (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A). Login to comment
133 Consistent with the previous report, all the mutant Pgp`s (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A) were expressed on the cell surface at a comparable level to that of wild-type (WT) Pgp (Figure 1A, upper panel). Login to comment
141 Human osteosarcoma (HOS) cells infected with vTF7-3 were transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes), pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNA. Login to comment
143 (A, upper panel) Cells were subjected to FACS analysis after staining with human Pgp external epitope-specific monoclonal antibody MRK-16 (14), as described under Experimental Procedures. (A, lower panel) Total cell lysates were prepared from each cell type, and immunoblot analysis with Pgp-specific monoclonal antibody C219 was performed as described under Experimental Procedures. (B) Similar to section A; cells were infected with vTF7-3, and transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes) pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNAs. Login to comment
156 The effects of both cis(Z)- and trans(E)-flupentixol on accumulation of Bodipy FL-verapamil in cells expressing V988A, Q990A, or V991A were identical to that observed in L975A (data not shown), suggesting that none of these substitutions affects inhibition of transport by flupentixol. Login to comment

[hide] Contribution to substrate specificity and transpor... Biochemistry. 1998 Nov 17;37(46):16400-9. Hafkemeyer P, Dey S, Ambudkar SV, Hrycyna CA, Pastan I, Gottesman MM
Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein.
Biochemistry. 1998 Nov 17;37(46):16400-9., 1998-11-17 [PMID:9819232]

Abstract [show]
P-glycoprotein (Pgp), the product of the MDR1 gene, confers multidrug resistance on cancer cells by ATP-dependent extrusion of anticancer drugs. Biochemical and genetic studies with Pgp have identified the putative transmembrane (TM) region 12 (residues 974-994) as a major region involved in drug interactions with amino acid residues conserved among Pgp family members shown to be essential for transport. To determine whether nonconserved residues might be involved in substrate specificity, seven amino acid residues were identified within TM 12 that were not strictly conserved among the MDR1 and MDR2 family of proteins from different mammalian species. We replaced all seven of these amino acid residues with alanine, one at a time and in combinations, and used a vaccinia virus based transient expression system to analyze function. None of the single replacements caused any alteration in transport function. However, when residues L975, V981, and F983 were replaced collectively, drug transport, drug-stimulated ATP hydrolysis, and photoaffinity labeling with the drug analogue, [125I]iodoarylazidoprazosin (IAAP), were abrogated, with little effect on [alpha-32P]-8-azido-ATP labeling and basal ATPase activity. Pairwise alanine substitutuions showed variable effects on function. Substitutions including L975A in combination with any one of the other two replacements had the least effect on Pgp function. The V981A and F983A double mutant showed the most effect on transport of fluorescent substrates. In contrast, alanine substitutions of all four nonconserved residues M986, V988, Q990, and V991 at the putative carboxy-terminal half of TM 12 showed no effect on drug transport except for a partial reduction in bodipy-verapamil extrusion. These results suggest that nonconserved residues in the putative amino-proximal half of TM 12 of Pgp play a more direct role in determining specificity of drug transport function than those in the putative carboxy-terminal half of TM 12.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
98 Alanine mutants were arranged in such a way that three alanine mutations were putatively located in the outer plasma membrane leaflet (L975A, V981A, and F983A) and four in the inner leaflet (M986A, V988A, Q990A, and V991A), assuming an R-helical structure to TM 12 (Figure 1b). Login to comment
121 Substitution of the four nonconserved amino acid residues (M986A, V988A, Q990A, and V991A) in the carboxy-terminal half of TM 12 had no effect on transport of calcein-AM, rhodamine 123, and bodipy-taxol. Login to comment
126 The V981-F983 double mutant was Table 1: Properties of Wild-Type and Mutant P-glycoproteinsa drug transporta cell surface expressionc rhodamine daunomycin bodipy-verapamil calcein-AM bodipy-taxol wild-type ++++ ++++ ++++ ++++ ++++ ++++ L975A ++++ ++++ ++++ ++++ ++++ ++++ V981A ++++ ++++ ++++ ++++ ++++ ++++ F983A ++++ ++++ ++++ ++++ ++++ ++++ M986A ++++ ++++ n.d. ++++ ++++ n.d. V988A ++++ ++++ n.d. ++++ ++++ n.d. Q990A ++++ ++++ n.d. ++++ ++++ n.d. V991A ++++ ++++ n.d. ++++ ++++ n.d. L975A, V981A, F983A ++++ no transport no transport ++ ++ ++ M986A, V988A, Q990A, V991A ++++ ++++ +++ ++ ++++ ++++ V981A, F983A ++++ + no transport ++ ++ +++ L975A, F983A ++++ + ++ ++++ +++ ++++ L975A, V981A ++++ ++ no transport ++++ +++ ++++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d., not determined. b Drug transport was determined by FACS. Login to comment
130 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A, - -), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A-V988A-Q990A-V991A, ‚‚‚), the double mutants L975A-V981A (- - -), L975A-F983A (-‚‚-), and V981A-F983A (-‚-). Login to comment
141 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant (M986A-V988A-Q990A-V991A) (s). Login to comment
146 The quadruple mutant, M986A-V988A-Q990A-V991A, in the carboxy-terminal half still retained a substantial ability to bind IAAP. Login to comment
159 ATP binding was equivalent for wild-type MDR1 and the MDR1 mutants L975A-V981A-F983A as well as for M986A-V988A-Q990A-V991A (Figure 7). Login to comment
174 (a) pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), and mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A). Login to comment
188 pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A), WT (wild-type human MDR1) in the presence of 250 µM EDTA and without MgCl2 to assess the specificity of the 170 kDa band representing Pgp as indicated with the arrow. Login to comment
193 (Middle panel) Vanadate-induced [R-32P]-8-azido-ADP labeling was performed at 37 °C. pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A). Login to comment
215 Changing all four amino acid residues M986A, V988A, Q990A, or V991A in the carboxy-terminal part of TM 12 still allows almost normal transport function of Pgp. Login to comment
228 The double mutants showed reduced drug transport suggesting that a change in any two of these three amino Table 2: Properties of Wild-Type and Mutant P-Glycoproteinsa photoaffinity labelinga ATP bindingb ATPase activityc wild-type ++++ ++++ ++++ L975A +++ n.d. +++ V981A +++ n.d. +++ F983A +++ n.d. +++ M986A n.d. n.d. n.d. V988A n.d. n.d. n.d. Q990A n.d. n.d. n.d. V991A n.d. n.d. n.d. L975A,V981A, F983A + ++++ + M986A, V988A, Q990A, V991A ++ ++++ ++ V981A, F983A +++ n.d. +++ L975A, F983A +++ n.d. +++ L975A, V981A +++ n.d. +++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d. not determined. b Photoaffinity labeling was done in HeLa crude membrane preparations using [125 I]iodoarylazidoprazosin. Login to comment

[hide] Evidence for modulatory sites at the lipid-protein... Biochemistry. 2012 Apr 3;51(13):2852-66. Epub 2012 Mar 22. Mandal D, Moitra K, Ghosh D, Xia D, Dey S
Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.
Biochemistry. 2012 Apr 3;51(13):2852-66. Epub 2012 Mar 22., [PMID:22360349]

Abstract [show]
The human multidrug transporter P-glycoprotein (Pgp or ABCB1) sets up pharmacological barriers to many clinically important drugs, a therapeutic remedy for which has yet to be formulated. For the rational design of mechanism-based inhibitors (or modulators), it is necessary to map the potential sites for modulator interaction and understand their modes of communication with the other functional domains of Pgp. In this study, combining directed mutagenesis with homology modeling, we provide evidence of two modulator-specific sites at the lipid protein interface of Pgp. Targeting 21 variant positions in the COOH-terminal transmembrane (TM) regions, we find residues M948 (in TM11) and F983, M986, V988, and Q990 (all four in TM12) critically involved in substrate-site modulation by a thioxanthene-based allosteric modulator cis-(Z)-flupentixol. Interestingly, for ATP-site modulation by the same modulator, only two (M948 and Q990) of those four residues appear indispensable, together with two additional residues, T837 and I864 in TM9 and TM10, respectively, suggesting independent modes of communication linking the allosteric site with the substrate binding and ATPase domains. None of the seven residues identified prove to be critical for modulation of the substrate or ATP sites by Pgp modulators that are transported by the pump, such as cyclosporin A or verapamil, indicating their specificity for cis-(Z)-flupentixol. On the other hand, ATP-site modulation by verapamil proves to be highly sensitive to replacement at positions F716 (in TM7) and I765 (in TM8), and to a more moderate extent at I764 and L772 (both in TM8). Homology modeling based on the known crystal structures of the bacterial multidrug transporter SAV1866 and the mouse Pgp homologue maps the identified residues primarily at the lipid-protein interface of Pgp, in two spatially distinct modulator-specific clusters. The two modulatory sites demonstrate negative synergism in influencing ATP hydrolysis, consolidating their spatial distinctness. Because Pgp is known to recruit drug molecules directly from the lipid bilayer, identification of modulatory sites at the lipid-protein interface and at the same time outside the conventional central drug binding cavity is mechanistically revealing.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
28 The desired nucleotide replacements were confirmed by Big-Dye version 3.1 (BD Sciences) nucleotide sequencing of the MDR1 open reading frame in recombinant plasmids pKM2-MDR1- V715A, -F716A, -I719A, -G723A, -I764A, -I765A, -I768A, -F770A, -L772A, -T837A, -I840A, -I864A, -I867A, -A871F, -T945A, -M948A, -F983A, -M986A, -V988A, -Q990A, and -V991A. Login to comment
102 A comparable level of basal binding of [125 I]IAAP to wild-type Pgp and Pgp mutants M948A, F983A, V988A, M986A, and Q990A (Figure 2B) rules out the possibility that the reduced level of stimulation in the mutants is due to loss of [125 I]IAAP binding and not stimulation per se. To investigate whether M948, Q990, F983, M986, and V988 are part of a general module involved in the regulation of substrate binding or are molecular components specific to cis- (Z)-flupentixol, we studied the effect of a structurally unrelated Pgp modulator, cyclosporin A, on binding of [125 I]IAAP to all 21 mutants. Login to comment
110 Stimulation of ATP Hydrolysis by cis-(Z)-Flupentixol and Verapamil cis-(Z)-flupentixol-mediated stimulation verapamil-mediated stimulation maximal stimulation (x-fold basal) concentration for half-maximal stimulation (μM) remark maximal stimulation (x-fold basal) concentration for half-maximal stimulation (μM) remark WT 7.3 ± 0.4 6.8 ± 1.5 5.6 ± 0.19 6.6 ± 1.04 V715A 6.2 ± 0.2 5.0 ± 0.9 6.4 ± 0.37 16.3 ± 3.3 V716A 5.1 ± 0.2 4.7 ± 1.1 NDb NDb a I719A 4.6 ± 0.08 4.7 ± 0.4 5.8 ± 0.26 6.5 ± 1.31 G723A 5.3 ± 0.3 10.93 ± 2.7 5.4 ± 0.1 11.6 ± 0.88 I764A 4.5 ± 0.4 4.1 ± 2 3.2 ± 0.26 27.9 ± 8.4 I765A 4.96 ± 0.2 2.3 ± 0.47 NDb NDb a I768A 4.8 ± 0.2 1.2 ± 0.43 4.8 ± 0.19 8.5 ± 1.4 F770A 6.6 ± 0.6 10.9 ± 3.9 8.6 ± 0.59 13.2 ± 3.2 L772A 3.6 ± 0.2 2.96 ± 0.9 3.2 ± 0.11 9.5 ± 1.6 T837A 1.1 ± 0.06 NDb a 2.6 ± 0.1 3.1 ± 0.9 I840A 4.0 ± 0.3 25.6 ± 6.5 6.9 ± 0.2 13.5 ± 0.5 I864A 0.6 ± 0.05 NDb a 4.1 ± 0.25 0.9 ± 1.04 I867A 10.2 ± 1.3 72.3 ± 18.5 10.2 ± 0.52 30.7 ± 3.1 A871F NDb NDb NDb NDb a T945A 5.0 ± 0.3 13.7 ± 3.1 6.4 ± 0.15 6.9 ± 0.71 M948A NDb NDb a 6.8 ± 1.5 44.4 ± 12.4 F983A 4.95 ± 0.36 19.59 ± 5.0 6.1 ± 0.38 6.6 ± 1.8 M986A 3.8 ± 0.3 2.6 ± 1.5 7.7 ± 0.76 30.0 ± 8.6 V988A 3.0 ± 0.2 21.4 ± 7.6 6.5 ± 0.31 16.9 ± 2.9 Q990A 1.8 ± 0.4 18.9 ± 2.6 a 7.7 ± 0.58 12.9 ± 3.7 V991A 3.9 ± 0.2 21.1 ± 5.0 5.9 ± 0.59 21.9 ± 7.2 a Mutants with <2-fold maximal stimulation (<25% of the wild-type level). Login to comment
113 Although a moderate effect was observed in Pgp mutants I867A, A871F, and V988A, none of the replacements proved to be absolutely critical for inhibition by cyclosporin A (Figure 3). Login to comment
224 Substitutions F983A, M986A, and V988A completely abrogate stimulation of substrate binding (Figure 2) with only modest effects on ATP-site stimulation (Figure 4), which indicates that the two modulatory events are not tightly coupled to each other. Login to comment

[hide] Molecular genetic analysis and biochemical charact... Semin Cell Dev Biol. 2001 Jun;12(3):247-56. Hrycyna CA
Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance.
Semin Cell Dev Biol. 2001 Jun;12(3):247-56., [PMID:11428917]

Abstract [show]
A variety of human cancers become resistant or are intrinsically resistant to treatment with conventional drug therapies. This phenomenon is due in large part to the overexpression of a 170 kDa plasma membrane ATP-dependent pump known as the multidrug resistance transporter or P-glycoprotein. P-glycoprotein is a member of the large ATP binding cassette (ABC) superfamily of membrane transporters. This review focuses on the use of structure-function analyses to elucidate further the mechanism of action of mammalian P-glycoproteins. Ultimately, a complete understanding of the mechanism is important for the development of novel strategies for the treatment of many human cancers.

Comments [show]

None has been submitted yet.

Sentences [show]
No. Sentence Comment
27 List of mutations in human, mouse and hamster P-gp`s that affect substrate specificity f aaa Mutation Regionb Sourcec Reference aa 78-97 EC 1 human MDR1 78 (ABC20)d Q128He TM 2 mouse mdr3 79 R138H IC 1 mouse mdr3 79 Q139H, R IC 1 mouse mdr3 79 G141V IC 1 human MDR1 25,80 Q145H IC 1 mouse mdr3 79 E155G, K IC 1 mouse mdr3 79 F159I IC 1 mouse mdr3 79 D174G IC 1 mouse mdr3 79 S176F, P IC 1 mouse mdr3 79 K177I IC 1 mouse mdr3 79 N179S IC1 mouse mdr3 79 N183S/G185V IC 1 human MDR1 81 G183D IC1 mouse mdr3 79 G185V IC 1 human MDR1 82-84 G187V IC 1 human MDR1 80 A192T TM 3 mouse mdr3 79 F204S EC 2 mouse mdr3 79 W208G EC 2 mouse mdr3 79 K209E EC 2 mouse mdr3 79 L210I TM 4 mouse mdr3 79 T211P TM 4 mouse mdr3 79 I214T TM 4 mouse mdr3 79 P223A TM 4 human MDR1 85 K285T IC 2 human MDR1 1 G288V IC 2 human MDR1 80 I299M, T319S, L322I, TM 5, EC3, IC 3 human MDR1 86 G324K, S351N V334 TM 6 human MDR1 1 F335A TM 6 human MDR1 25 F335 TM 6 human MDR1 87 V338A TM 6 human MDR1 88 G338A, A339P TM 6 hamster PGY 1 89,90 A339P TM 6 hamster PGY 1 90 G341V TM 6 human MDR1 88 K536R,Q N-NBD human MDR1 91 ERGA→DKGT N-NBD mouse mdr3 92 (aa 522-525) T578C N-NBD mouse mdr3 92 G812V IC 4 human MDR1 80 G830V IC 4 human MDR1 25,80 P866A TM 10 human MDR1 85 F934A TM 11 mouse mdr3 93 G935A TM 11 mouse mdr3 93 I936A TM 11 mouse mdr3 93 F938A TM 11 mouse mdr3 93 S939A TM 11 mouse mdr3 93 S939F TM 11 mouse mdr3 94,95 S941F TM 11 mouse mdr1 94,95 T941A TM 11 mouse mdr3 93 Q942A TM 11 mouse mdr3 93 Table 1-continued aaa Mutation Regionb Sourcec Reference A943G TM 11 mouse mdr3 93 Y946A TM 11 mouse mdr3 93 S948A TM 11 mouse mdr3 93 Y949A TM 11 mouse mdr3 93 C952A TM 11 mouse mdr3 93 F953A TM 11 mouse mdr3 93 F983A TM 12 human MDR1 96 L975A, V981A, F983A TM 12 human MDR1 96 M986A, V988A, TM 12 human MDR1 96 Q990A, V991A V981A, F983A TM 12 human MDR1 96 L975A, F983A TM 12 human MDR1 96 L975A, V981A TM 12 human MDR1 96 F978 TM 12 human MDR1 1 F978A TM 12 human MDR1 25 a aa, amino acid. Login to comment